Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure

Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure

Background & Aims: Voxilaprevir/velpatasvir/sofosbuvir (VOX/VEL/SOF) is highly effective for re-treatment of direct-acting antiviral (DAA)-experienced patients with chronic HCV infection. In the present study, predictors of virologic treatment response were analyzed in an integrative analysi...

Full description

Bibliographic Details
Main Authors: Christiana Graf, Roberta D’Ambrosio, Elisabetta Degasperi, Stefania Paolucci, Jordi Llaneras, Johannes Vermehren, Georg Dultz, Kai-Henrik Peiffer, Fabian Finkelmeier, Eva Herrmann, Stefan Zeuzem, Maria Buti, Pietro Lampertico, Julia Dietz, Christoph Sarrazin
Format: Article
Language:English
Published: Elsevier 2024-03-01
Series:JHEP Reports
Subjects:
Re-treatment
Hepatitis C virus
DAA treatment failure
Voxilaprevir/velpatasvir/sofosbuvir
Online Access:http://www.sciencedirect.com/science/article/pii/S2589555923003257

Internet

http://www.sciencedirect.com/science/article/pii/S2589555923003257

Similar Items